SOPH SOPHiA Genetics SA

  1. Stocks
  2. Healthcare
  3. NASDAQ: SOPH

Price (delayed)

$8.08

Market cap

$687.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.15

Enterprise value

$641.99M

?
Relative Growth: Rel. Growth: 53
Relative Strength: Rel. Strength: 95
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 20
Highlights
SOPH's equity has surged by 82% since the previous quarter and by 8% year-on-year
SOPHiA Genetics's revenue has increased by 24% YoY and by 6% QoQ
The company's quick ratio rose by 39% QoQ but it fell by 21% YoY
SOPHiA Genetics's EPS has decreased by 4.5% YoY but it has increased by 2.5% from the previous quarter
The net income has contracted by 10% YoY
Sector: Healthcare
Industry: Health Information Services
Website: https://www.sophiagenetics.com
Peers: PHR PHUN

Key stats

What are the main financial stats of SOPH

SOPH stock price

How has the SOPHiA Genetics stock price performed over time
Intraday
0.12%
1 week
1.32%
1 month
-6.59%
1 year
104.04%
YTD
73.02%
QTD
40.03%

Financial performance

How have SOPHiA Genetics's revenue and profit performed over time
Revenue
$86.17M
Gross profit
$57.41M
Operating income
-$73.71M
Net income
-$80.88M
Gross margin
66.6%
Net margin
-93.9%
SOPHiA Genetics's revenue has increased by 24% YoY and by 6% QoQ
SOPH's gross profit is up by 22% year-on-year and by 5% since the previous quarter
The operating margin has grown by 11% YoY and by 3.8% from the previous quarter
SOPHiA Genetics's net margin has increased by 11% YoY and by 6% QoQ

Price vs fundamentals

How does SOPH's price correlate with its fundamentals

Growth

What is SOPHiA Genetics's growth rate over time

Valuation

What is SOPHiA Genetics stock price valuation
P/E
N/A
P/B
6.98
P/S
6.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.45
SOPHiA Genetics's EPS has decreased by 4.5% YoY but it has increased by 2.5% from the previous quarter
The P/B is 149% more than the 5-year quarterly average of 2.8 and 14% more than the last 4 quarters average of 6.1
SOPH's equity has surged by 82% since the previous quarter and by 8% year-on-year
The P/S is 53% above the last 4 quarters average of 4.4
SOPHiA Genetics's revenue has increased by 24% YoY and by 6% QoQ

Efficiency

How efficient is SOPHiA Genetics business performance
SOPHiA Genetics's ROE has plunged by 73% YoY but it has increased by 2.8% from the previous quarter
SOPHiA Genetics's ROS has increased by 14% YoY and by 6% from the previous quarter
The ROIC has grown by 12% YoY but it has contracted by 4.1% from the previous quarter
The ROA has declined by 6% year-on-year but it rose by 3.3% since the previous quarter

Dividends

What is SOPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SOPH.

Financial health

How did SOPHiA Genetics financials performed over time
SOPH's total assets is 72% greater than its total liabilities
The company's quick ratio rose by 39% QoQ but it fell by 21% YoY
The current ratio is up by 31% since the previous quarter but it has declined by 21% year-on-year
SOPHiA Genetics's debt is 26% lower than its equity
SOPH's equity has surged by 82% since the previous quarter and by 8% year-on-year
The debt to equity is down by 46% since the previous quarter and by 11% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.